|本期目录/Table of Contents|

[1]于志君,崔力文,程凯慧,等.季节性流感疫苗研究进展[J].传染病信息,2018,05:470-474.
 YU Zhi-jun,CUI Li-wen,CHENG Kai-hui*,et al.Research progress of seasonal influenza vaccine[J].Infectious Disease Information,2018,05:470-474.
点击复制

季节性流感疫苗研究进展(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2018年05期
页码:
470-474
栏目:
专题综述
出版日期:
2018-10-30

文章信息/Info

Title:
Research progress of seasonal influenza vaccine
作者:
于志君崔力文程凯慧高玉伟
2 5 0 0 2 3 济南,山东省农业科学院家禽研究所(于志君);130062 长春,军事科学院军事医学研究院军事兽医研 究所(高玉伟);2 5 0 1 3 2 济南,山东省农业科学院奶牛研究中心(程凯慧);264419,威海市文登区界石镇卫生院(崔力文)
Author(s):
YU Zhi-jun CUI Li-wen CHENG Kai-hui* GAO Yu-wei*
Institute of Poultry Science, Shandong Academy of Agricultural Sciences, Jinan 250023, China
关键词:
流感病毒季节性流感疫苗
Keywords:
influenza virus seasonal influenza vaccine
分类号:
 R373.1;R186
DOI:
10.3969/j.issn.1007-8134.2018.05.016
文献标识码:
A
摘要:
 季节性流感病毒对公共卫生安全构成严重威胁。季节性流感疫苗则是目前防控流感病毒最有效的手段。常用 的季节性流感疫苗包括裂解疫苗、亚单位疫苗和减毒活疫苗;新型季节性流感疫苗包括细胞培养流感疫苗、病毒样颗粒疫苗 和复制缺陷型疫苗等。本文从常用季节性流感疫苗类型以及新型季节性流感疫苗研究进展两个方面介绍季节性流感疫苗研究 进展,以期为季节性流感病毒的防控工作提供参考和借鉴。
Abstract:
 The seasonal influenza viruses pose a serious threats to public health, and seasonal influenza vaccine is currently the most effective means of preventing and controlling influenza viruses. Typical seasonal influenza vaccines include split vaccine, subunit vaccine, and live attenuated vaccine. Furthermore, new seasonal influenza vaccines include cell culture influenza vaccine, virus-like particle vaccine, and replication-deficient vaccine. In order to provide reference for the prevention and control of seasonal influenza viruses, we introduce the research progress of seasonal influenza vaccine regarding the types of typical seasonal influenza vaccines and the research progress of new seasonal influenza vaccine.     

参考文献/References


[1] Ko EJ, Kang SM. Immunology and efficacy of MF59-adjuvantedvaccines[J]. Hum Vaccin Immunother, 2018, 17:1-5.
[2] Chong Y, Ikematsu H. Is seasonal vaccination a contributing factorto the selection of influenza epidemic variants[J]. Hum VaccinImmunother, 2018, 14:518-522.
[3] Snoeck CJ, Oliva J, Pauly M, et al. Influenza D virus circulation incattle and swine, luxembourg, 2012-2016[J]. Emerg Infect Dis,2018, 24:1388-1389.
[4] Gao J, Xu K, Sun H, et al. Generation and characterization ofmonoclonal antibodies against the NS1 protein of H17N10 batinfluenza virus[J]. Acta Biochim Biophys Sin (Shanghai), 2017,49:649-651.
[5] Wu Y, Wu Y, Tefsen B, et al. Bat-derived influenza-like virusesH17N10 and H18N11[J]. Trends Microbiol, 2014, 22:183-191.
[6] Rey D, Fressard L, Cortaredona S, et al. Vaccine hesitancy in theFrench population in 2016, and its association with vaccine uptakeand perceived vaccine risk-benefit balance[J]. Euro Surveill2018, 23(17):pii=17-00816.
[7] Moa AM, Chughtai AA, Muscatello DJ, et al. Immunogenicity andsafety of inactivated quadrivalent influenza vaccine in adults: asystematic review and meta-analysis of randomised controlled trials [J]. Vaccine, 2016, 34(35):4092-4102.
[8] Broecker F, Liu STH, Sun W, et al. Immunodominance of antigenicsite B in the hemagglutinin of the current H3N2 influenza virus inhumans and mice[J]. J Virol, 2018, 92(20):pii:e01100-18.
[9] Ho A, Aston SJ, Jary H, et al. Impact of human immunodeficiencyvirus on the burden and severity of influenza illness in malawianadults: a prospective cohort and parallel case-control study[J].Clin Infect Dis, 2018, 66(6):865-876.
[10] Jackson ML, Phillips CH, Benoit J, et al. Burden of medicallyattended influenza infection and cases averted by vaccination -United States, 2013/14 through 2015/16 influenza seasons[J].Vaccine, 2018, 36(4):467-472.
[11] Manceur AP, Kamen AA. Critical review of current and emergingquantification methods for the development of influenza vaccinecandidates[J].Vaccine, 2015, 33(44):5913-5919.
[12] Wendlandt R, Cowling BJ, Chen Y, et al. Knowledge, attitudes andpractices related to the influenza virus and vaccine among olderadults in Eastern China[J].Vaccine, 2018, 36(19):2673-2682.
[13] Mo Z, Nong Y, Liu S, et al. Immunogenicity and safety of a trivalentinactivated influenza vaccine produced in Shenzhen, China[J].Hum Vaccin Immunother, 2017, 13:1-7.
[14] Feng L, Mounts AW, Feng Y, et al. Seasonal influenza vaccinesupply and target vaccinated population in China, 2004-2009[J].Vaccine, 2010, 28 (41):6778-6782.
[15] 李硕,张云辉,王永怡,等. 2017 年全球传染病热点回顾[J].传染病信息,2018,31(1):5-10.
[16] Flannery B, Chung JR, Belongia EA, et al. Interim estimates of2017-18 seasonal influenza vaccine effectiveness - United States,February 2018[J]. MMWR Morb Mortal Wkly Rep, 2018,67(6):180-185.
[17] Vaudry W, Stirling R, National Advisory Committee on I. Summaryof the NACI statement on seasonal influenza vaccine for 2017-2018[J]. Can Commun Dis Rep, 2017, 43:96-103.
[18] Sycheva AL, Pogorelyy MV, Komech EA, et al. Quantitative profiling reveals minor changes of T cell receptor repertoire inresponse to subunit inactivated influenza vaccine[J]. Vaccine,2018, 36(12):1599-1605.
[19] Baxter R, Eaton A, Hansen J, et al. Safety of quadrivalent liveattenuated influenza vaccine in subjects aged 2-49years[J].Vaccine, 2017, 35(9):1254-1258.
[20] Jin H, Subbarao K. Live attenuated influenza vaccine[J]. CurrTop Microbiol Immunol, 2015, 386(5):181-204.
[21] Nogales A, Rodriguez L, Chauche C, et al. Temperature-sensitivelive-attenuated canine influenza virus H3N8 vaccine[J]. J Virol,2017, 91(4):pii:e02211-16.
[22] Maassab HF, DeBorde DC. Development and characterization ofcold-adapted viruses for use as live virus vaccines[J]. Vaccine,1985, 3(5):355-369.
[23] Lee YH, Jang YH, Seong BL. Cell-cultured, live attenuated,X-31ca-based H5N1 pre-pandemic influenza vaccine[J].Virology, 2017, 504:73-78.
[24] Koudstaal W, Hartgroves L, Havenga M, et al. Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccinestrains by reverse genetics[J]. Vaccine, 2009, 27(19):2588-2593.
[25] Reisinger KS, Block SL, Izu A, et al. Subunit influenza vaccinesproduced from cell culture or in embryonated chicken eggs:comparison of safety, reactogenicity, and immunogenicity[J]. JInfect Dis, 2009, 200(6):849-857.
[26] Romanova J, Katinger D, Ferko B, et al. Live cold-adaptedinfluenza A vaccine produced in Vero cell line[J]. Virus Res,2004, 103(1-2):187-193.
[27] Lindsay BJ, Bonar MM, Costas-Cancelas IN, et al. Morphologicalcharacterization of a plant-made virus-like particle vaccinebearing influenza virus hemagglutinins by electron microscopy[J].Vaccine, 2018, 36(16):2147-2154.
[28] Lopez-Macias C, Ferat-Osorio E, Tenorio-Calvo A, et al. Safetyand immunogenicity of a virus-like particle pandemic influenza A(H1N1) 2009 vaccine in a blinded, randomized, placebo-controlledtrial of adults in Mexico[J]. Vaccine, 2011, 29(44):7826-7834.
[29] Ross TM, Mahmood K, Crevar CJ, et al. A trivalent virus-likeparticle vaccine elicits protective immune responses againstseasonal influenza strains in mice and ferrets[J]. PLoS One,2009, 4:e6032.
[30] Quan FS, Kim YC, Song JM, et al. Long-term protective immunityfrom an influenza virus-like particle vaccine administeredwith a microneedle patch[J]. Clin Vaccine Immunol, 2013,20(9):1433-1439.
[31] Wang BZ, Quan FS, Kang SM, et al. Incorporation of membraneanchoredflagellin into influenza virus-like particles enhances thebreadth of immune responses[J]. J Virol, 2008, 82(23):11813-11823.
[32] Wacheck V, Egorov A, Groiss F, et al. A novel type of influenzavaccine: safety and immunogenicity of replication-deficientinfluenza virus created by deletion of the interferon antagonist NS1 [J]. J Infect Dis, 2010, 201(3):354-362.
[33] Vesikari T, Groth N, Karvonen A, et al. MF59-adjuvantedinfluenza vaccine (FLUAD) in children: safety and immunogenicityfollowing a second year seasonal vaccination[J]. Vaccine, 2009,27(45):6291-6295.

备注/Memo

备注/Memo:
[ 基金项目] 山东省自然科学基金青年基金(ZR2018QC005);山东省农业科学院高层次人才及创新团队引进计划
[ 作者单位] 2 5 0 0 2 3 济南,山东省农业科学院家禽研究所(于志君);130062 长春,军事科学院军事医学研究院军事兽医研 究所(高玉伟);2 5 0 1 3 2 济南,山东省农业科学院奶牛研究中心(程凯慧);264419,威海市文登区界石镇卫生院(崔力文)
[ 通信作者] 程凯慧,E-mail: chengkaihui@126.com;高玉伟,E-mail: gaoyuwei@gmail.com
更新日期/Last Update: 2018-10-30